Business Description
Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US45845P1084
Share Class Description:
ICPT: Ordinary SharesDescription
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.44 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 3.12 | |||||
| Debt-to-EBITDA | -4.68 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.97 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EBITDA Growth Rate | 21.6 | |||||
| 3-Year EPS without NRI Growth Rate | 39.1 | |||||
| 3-Year FCF Growth Rate | 52.4 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.73 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76 | |||||
| 9-Day RSI | 75.25 | |||||
| 14-Day RSI | 75.8 | |||||
| 6-1 Month Momentum % | 14.54 | |||||
| 12-1 Month Momentum % | 15.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.22 | |||||
| Quick Ratio | 4.22 | |||||
| Cash Ratio | 3.55 | |||||
| Days Sales Outstanding | 33.1 | |||||
| Days Payable | 6772.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 | |||||
| Shareholder Yield % | 35.21 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.8 | |||||
| Operating Margin % | -17.34 | |||||
| Net Margin % | -19.39 | |||||
| FCF Margin % | -19.74 | |||||
| ROE % | -75.63 | |||||
| ROA % | -12.35 | |||||
| ROIC % | -45.44 | |||||
| ROC (Joel Greenblatt) % | -4931.08 | |||||
| ROCE % | -15.47 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 7.87 | |||||
| PS Ratio | 2.49 | |||||
| PB Ratio | 11.06 | |||||
| Price-to-Tangible-Book | 11.05 | |||||
| EV-to-EBIT | -14.43 | |||||
| EV-to-Forward-EBIT | 5.65 | |||||
| EV-to-EBITDA | -14.54 | |||||
| EV-to-Forward-EBITDA | 5.64 | |||||
| EV-to-Revenue | 2.19 | |||||
| EV-to-Forward-Revenue | 1.9 | |||||
| EV-to-FCF | -11.09 | |||||
| Price-to-Median-PS-Value | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 12.75 | |||||
| Price-to-Net-Cash | 633.33 | |||||
| Earnings Yield (Greenblatt) % | -6.93 | |||||
| FCF Yield % | -7.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ICPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intercept Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 317.684 | ||
| EPS (TTM) ($) | -1.48 | ||
| Beta | 0 | ||
| Volatility % | 108.39 | ||
| 14-Day RSI | 75.8 | ||
| 14-Day ATR ($) | 0.162393 | ||
| 20-Day SMA ($) | 18.899 | ||
| 12-1 Month Momentum % | 15.92 | ||
| 52-Week Range ($) | 8.8216 - 21.86 | ||
| Shares Outstanding (Mil) | 41.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intercept Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intercept Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intercept Pharmaceuticals Inc Frequently Asked Questions
What is Intercept Pharmaceuticals Inc(ICPT)'s stock price today?
The current price of ICPT is $19.00. The 52 week high of ICPT is $21.86 and 52 week low is $8.82.
When is next earnings date of Intercept Pharmaceuticals Inc(ICPT)?
The next earnings date of Intercept Pharmaceuticals Inc(ICPT) is 2024-08-02 Est..
Does Intercept Pharmaceuticals Inc(ICPT) pay dividends? If so, how much?
Intercept Pharmaceuticals Inc(ICPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers